Objective: The purpose of this survey was to estimate the prevalence of viral load (VL) suppression and emergence of HIV drug resistance (HIVDR) among individuals receiving antiretroviral therapy (ART) for 36 months or longer in Viet Nam using a nationally representative sampling method. Methods: The survey was conducted between May and August 2014 using a two-stage cluster design. Sixteen ART clinics were selected using probability proportional to proxy size sampling, and patients receiving ART for at least 36 months were consecutively enrolled. Epidemiological information and blood specimens were collected for HIV-1 VL and HIVDR testing; HIVDR was defined by the Stanford University HIVDR algorithm. Results: Overall, 365 eligible individuals were recruited with a mean age of 38.2 years; 68.4% were men. The mean time on ART was 75.5 months (95% confidence interval [CI]: 69.0–81.9 months), and 93.7% of the patients were receiving non-nucleoside reverse transcriptase inhibitor-based regimens. Of the 365 individuals, 345 (94.7%, 95% CI: 64.1–99.4%) had VL below 1000 copies/mL and 19 (4.6%, 95% CI: 2.8-–7.5) had HIVDR mutations. Discussion Our nationally representative survey found a high level of VL suppression and a low prevalence of HIVDR among individuals who received ART for at least 36 months in Viet Nam. Continued surveillance for HIVDR is important for evaluating and improving HIV programs.

Introduction: Laboratory capacity is needed in central Viet Nam to provide early warning to public health authorities of respiratory outbreaks of importance to human health, for example the outbreak of influenza A(H1N1) pandemic in 2009. Polymerase chain reaction (PCR) procedures established as part of a capacity-building process were used to conduct prospective respiratory surveillance in a region where few previous studies have been undertaken. Methods: Between October 2008 and September 2010, nose and throat swabs from adults and children (approximately 20 per week) presenting with an acute respiratory illness to the Ninh Hoa General Hospital were collected. Same-day PCR testing and result reporting for 13 respiratory viruses were carried out by locally trained scientists. Results: Of 2144 surveillance samples tested, 1235 (57.6%) were positive for at least one virus. The most common were influenza A strains (17.9%), with pandemic influenza A(H1N1) 2009 and seasonal H3N2 strain accounting for 52% and 43% of these, respectively. Other virus detections included: rhinovirus (12.4%), enterovirus (8.9%), influenza B (8.3%), adenovirus (5.3%), parainfluenza (4.7%), respiratory syncytial virus (RSV) (3.9%), human coronavirus (3.0%) and human metapneumovirus (0.3%). The detection rate was greatest in the 0–5 year age group. Viral co-infections were identified in 148 (6.9%) cases. Discussion: The outbreak in 2009 of the influenza A(H1N1) pandemic strain provided a practical test of the laboratory’s pandemic plan. This study shows that the availability of appropriate equipment and molecular-based testing can contribute to important individual and public health outcomes in geographical locations susceptible to emerging infections.

Background: Vietnam is located in the endemic region of hepatitis B virus (HBV) infection, but no data of occult HBV infection was reported at present. Objectives: To investigate the prevalence of occult HBV infection in different ethnics of people and generations. Subjects and method: 80 voluteers with HbsAg negative from five different ethnics: Kinh, Tay, Mong, Giay and Dao in a Chino \ufffd?Vietnamses border province (Lao Cai) were enrolled in the study. After HBV-DNA was extracted, nested PCR of S gene and of Core-promoter/Pre-core region were used to detect HBV-DNA. Specifying nucleotide sequence was confirmed by direct sequencing. Results:The prevalence of occult HBV infection in population study was very high 73/80 (91,3%) by nested PCR of Core-promoter/Pre-core, significantly more sensitive than nested PCR of S gene (26,3%) (p<0,0001). The prevalence of occult HBV infection was notdifferent between ethnics of people or between children, adults. Conclusion: Occult HBV infection in Vietnamese is very common; however, nationwide further studies should be carried out to confirm this preliminary results and evaluate the impact of occult HBV infection in Vietnam.
Hepatitis B virus ; Hepatitis B Surface Antigens ;

Background: Hepatitis B is an infectious illness caused by hepatitis B virus (HBV) which infects the liver of hominoidea, including humans, and causes an inflammation called hepatitis. Objectives: The aim of study is to clarify clinical features and molecular characteristics of HBV in chronic HBV-infected patients with A 1899 mutation. Subjects and method: HBV genotype, HBV-ONA level, HBeAg and anti-HBe in 29 chronic HBV-infected patients were determined by PCR-RFLP, Real-time PCR and ELISA, respectively. Mutations were analyzed by direct sequencing. Results: Mutations in core-promoter/precore regions of HBV genome can suppress HBeAg secretion and stimulate HBV-ONA replication. The prevalence of hepatocel- lular carcinoma (HCc): 10/29, liver cirrhosis (LC) : 15/29 are significantly higher than that in chronic hepatitis (CH) : 4/29 (P < 0.001). HbeAg seroconversion rate in CH (75%) is higher than that in HCC \r\n', u'(40%) and in LC (53.3%), but not significant (P > 0.05). ALT level is the highest in CH and the lowest in HCC \r\n', u'(P = 0.02), 8/10 (80%) HCC patients have normal range of ALT. HBV-ONA level in HCC and in LC is significantly higher than that in CH (P = 0.024). The emerging of A 1899 is often accompanied by C/G1753 mutation (37.9%) and dual core-promoter mutation T1762A1764 (79.3%). Conclusion: A1899 mutation can play a role in the pathogenesis of liver diseases in chronic HBV-infected Vietnamese.\r\n', u'
Hepatitis B virus/ growth & ; development ; physiology ; Hepatitis B ; Chronic/ pathology ; transmission

Background: Hepatocellular carcinoma (HCC) is the most common primary hepatic tumor and one of the most common cancers worldwide. HCC is a primary malignancy of hepatocellular origin. Objectives:The aim of study is to combinate therapy of transarterial chemoembolization and percutaneousethanol injection afterward emerging metatasis caused by fine needle aspiration cytology. Subjects and method: A 50 years old male patient with hepatocellular carcinoma having a diameter of tumor more than 5 cm was treated by combination of transarterial chemoembolization and percutaneous ethanol injection from December 2000. Results & Conclusion: Results of study showed that: Transarterial chemoembolization and percutaneous ethanol injection are the two of non-surgical methods for treatment of hepatocellular carcinoma which are most commonly available in applied clinical activities at present. Up to now, the patient's life expectancy after therapy is more than 6 years that means the result of treatment is very good. However, the emerging metatasis into the anterior-right-Iower chest wall that was caused by fine needle aspiration cytology should be reviewed for further evaluating clinical experience, especially in cases with quite clear imaging features of untrasonography and significantly elevated AFP level higher than 200 ng/rnl.
Carcinoma ; Hepatocellular/ pathology ; therapy

The quantification of markers of breast cancer in healthy people (26 people for CA 15-3 and 28 people for CEA) by IRMA has shown that the serum concentration of CA15-3 and CEA was 19.12+/- 15.44 u/ml and 4.19 +/- 2.35 ng/ml, respectively. The medium (4.48), mininum (0.00) and maxinum (8.37) ng/ml. These results can be used to compared with markers in patients with breast cancer. There was no difference of these between men and women.
Breast Neoplasms ; breast

Serum levels of tumor maker CA 19-9 were quantified in healthy young and middle adults, including both genders. Participants had to have no sign of tumor or inflammatory diseases. Technically, level of CA 19-9 as quantifying by IRMA kid of CISbio International was reliable with%CV ranged from 0.1 to 5.4. Average value of CA 19-9 is 17.11+/-11.06. Level in high area was no more than 35.7 U/mL. Upper and lower marginal areas were 26.61 U/mL and 5.68 U/mL, respectively. There was no significant difference between two genders
Immunoradiometric Assay ; Serum

The quantitative analysis of the concentration tumor marker CA15-3 by the immunoradioactive method in the serum of 26 normal persons without the tumor, hepatic diseases and chronic diseases ages of 18-50 has shown that this is method with high accuracy. The radioactive activity is direct proportional with the concentration of CA 15-3; The concentration of CA 15-3 in the normal people is 19,12+/-15,54 u/ml in which 90% persons have concentration under 30% u/ml. The concentration of CA 15-3 is most common in 4,71 u/ml.
Tumor Markers, Biological ; Chronic Disease

Subjects: Normal people without the benign or malignant tumor; standard sample of CA72-4 with concentrations: 0,3; 25; 50 100 u/ml. The results have shown that the standard chart has relatively same as theory; the change factor CV had value within allowed limit in the range of low concentration of CA 72-4 was 4,05+/- 3,06U/ml. The medium value was 4,92 u/ml. The normal range is from 0 to 9 u/ml. There is insignificant different between women and men.
Neoplasms ; Immunoradiometric Assay ; Tumor Markers, Biological

Participants were 28 healthy people involved in genders, included smokers and non-smokers with age ranged from 18 to 50 years. Standard curve was established using 6 prepared sample kits of manufacturer with levels of 0, 4, 20, 80, 140 and 200ng/ml. The findings suggested that for technical standard, CEA quantification with IRMA using kits of France-based CIS Bio International was reliable, quality of kits and qualification skill is good. Average level of CEA maker in 28 subjects above is 4.19+/-2.35ng/ml with mean-point of 4.48, ranged from 0.00 to 8.37ng/ml. The most common level is 6.37ng/ml. Upper-marginal level is 2.59ng/ml and under-marginal level is 3.36ng/ml. There was insignificant difference between male and female.
Administrative Personnel ; Carcinoembryonic Antigen ; Immunoradiometric Assay ; neoplasms